OncoZenge AB
Clinical-stage pharma company developing non-opioid treatments for oral pain.
ONCOZ | ST
Overview
Corporate Details
- ISIN(s):
- SE0015504097
- LEI:
- 2549003980RBCR6NIF38
- Country:
- Sweden
- Address:
- Gustavslundsvagen 34, 5 tr, 167 51 Bromma
- Website:
- https://oncozenge.se/
- Sector:
- Manufacturing
Description
OncoZenge AB is a clinical-stage pharmaceutical company developing innovative treatments for oral pain. The company's lead product candidate, BupiZenge™, is a lozenge formulation based on the well-established local anesthetic bupivacaine. It is designed to provide targeted, local pain relief for the primary indication of oral mucositis, a severe and painful side effect of cancer treatments such as chemotherapy and radiotherapy. BupiZenge™ aims to address a significant unmet medical need for a safe, effective, and non-opioid treatment to improve patients' quality of life. Having completed Phase 2 trials, the product is advancing towards a pivotal Phase 3 study following regulatory guidance from the EMA and FDA. The technology also has potential applications in other oral pain conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all OncoZenge AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for OncoZenge AB
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for OncoZenge AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-04-07 | Stian Kildal | Other | Buy | 20,439 | 85,026.24 SEK |
Peer Companies
